Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.4, 2004-01, pp. : 229-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tegaserod effective in irritable bowel syndrome

Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Tegaserod relieves global symptoms of Irritable Bowel Syndrome

Inpharma, Vol. 1, Iss. 1350, 2002-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal Berrada Driss Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

By Lynd Larry D. Najafzadeh Mehdi Colley Lindsey Byrne Michael F. Willan Andrew R. Sculpher Mark J. Johnson F. Reed Hauber A. Brett

Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. : 411-417

Blackwell Publishing

Access to resources Recommend Favorite

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

By McLaughlin John Houghton Lesley A

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 313-327

Informa Healthcare

Access to resources Recommend Favorite